IGC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IGC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. IGC Pharma's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $7.38 Mil. IGC Pharma's Total Assets for the quarter that ended in Sep. 2024 was $10.37 Mil. Therefore, IGC Pharma's Equity to Asset Ratio for the quarter that ended in Sep. 2024 was 0.71.
The historical rank and industry rank for IGC Pharma's Equity-to-Asset or its related term are showing as below:
During the past 13 years, the highest Equity to Asset Ratio of IGC Pharma was 0.98. The lowest was 0.62. And the median was 0.84.
The historical data trend for IGC Pharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC Pharma Annual Data | |||||||||||||||||||||
Trend | Mar15 | Mar16 | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | Mar23 | Mar24 | |||||||||||
Equity-to-Asset | Get a 7-Day Free Trial | 0.92 | 0.92 | 0.89 | 0.87 | 0.74 |
IGC Pharma Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.85 | 0.80 | 0.74 | 0.74 | 0.71 |
For the Biotechnology subindustry, IGC Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, IGC Pharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where IGC Pharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
IGC Pharma's Equity to Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as
Equity to Asset (A: Mar. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 7.321 | / | 9.902 | |
= | 0.74 |
IGC Pharma's Equity to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as
Equity to Asset (Q: Sep. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 7.377 | / | 10.369 | |
= | 0.71 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IGC Pharma (AMEX:IGC) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of IGC Pharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
James P Moran | director | 914 SPRING HILL ROAD, MCLEAN VA 22102 |
John Edward Lynch | director | 14 PARK AVENUE, REHOBOTH BEACH DE 19971 |
Richard K Prins | director | |
Ram Mukunda | director, officer: Exec. Chairman & CEO | |
Claudia Grimaldi | officer: Vice president and PFO | PO BOX 60642, POTOMAC MD 20859 |
Rohit Goel | officer: Manager & PAO | PO BOX 60642, POTOMAC MD 20859 |
John Cherin | officer: CFO, Treasurer and PAO | 662 LIVE OAK DRIVE, MCLEAN VA 22101 |
Shu Kwong Ngai | director, officer: Interim CFO | 4336 MONTGOMERY AVENUE, BETHESDA MD 20814 |
Ranga C Krishna | director | 330 THORNTON ROAD, ENGLEWOOD X1 07631 |
Sudhakar V Shenoy | director | 10411 MOTOR CITY DRIVE, BETHESDA MD 20817 |
Suhail Nathani | director | INDIA GLOBALIZATION CAPITAL, INC., 4336 MONTGOMERY AVE., BETHESDA MD 20814 |
Nisswa Acquisition Master Fund Ltd. | 10 percent owner | C/O MAPLES CORPORATE SVCS LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104 |
Smith Edward B Iii | 10 percent owner | C/O BRIGHTLINE CAPITAL MANAGEMENT, LLC, 1120 AVE OF THE AMERICAS, SUITE 1505, NEW YORK NY 10036 |
Ag Ubs | 10 percent owner | 600 WASHINGTON BLVD., STAMFORD CT 06901 |
Pine River Master Fund Ltd. | 10 percent owner | C/O PINE RIVER CAPITAL MANAGEMENT L.P., 601 CARLSON PARKWAY, 7TH FLOOR, MINNETONKA MN 55305 |
From GuruFocus
By ACCESSWIRE • 10-03-2024
By Marketwired Marketwired • 11-30-2018
By Marketwired Marketwired • 12-14-2018
By Marketwired Marketwired • 12-18-2018
By PRNewswire PRNewswire • 02-21-2022
By Marketwired Marketwired • 11-10-2018
By Marketwired Marketwired • 12-07-2018
By Marketwired Marketwired • 12-07-2018
By Marketwired Marketwired • 11-20-2018
By Marketwired Marketwired • 11-13-2018
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.